TLPH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings...

Stats
Today's Volume	66 582.00
Average Volume	97 401.00
Market Cap	17.31M
Next earnings date	( $-0.280 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00900 (0.87%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Nantahala Capital Management, Llc	Buy	324 675	2024 Pre-Funded Warrants
2024-03-15	Nantahala Capital Management, Llc	Buy	755 000	Common Stock
2024-03-15	Nantahala Capital Management, Llc	Sell	755 000	Put Option (obligation to buy)
2024-03-12	Angotti Vincent J.	Buy	8 000	Common Stock
2024-03-11	Angotti Vincent J.	Buy	1 000	Common Stock

INSIDER POWER
41.09
Last 32 transactions
Buy: 12 440 706 \| Sell: 5 181 856

Volume Correlation

Long: 0.12 (neutral)

Short: -0.61 (weak negative)

Signal:(54.051) Neutral

Talphera, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Talphera, Inc. Correlation - Currency/Commodity

0.19
( neutral )

0.26
( neutral )

0.00
( neutral )

0.27
( neutral )

0.26
( neutral )

-0.07
( neutral )

Talphera, Inc. Financials

Annual	2023
Revenue:	$651 000
Gross Profit:	$340 000 (52.23 %)
EPS:	$-1.290

FY	2023
Revenue:	$651 000
Gross Profit:	$340 000 (52.23 %)
EPS:	$-1.290

Financial Reports:

No articles found.

Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.

Realtime updates for Talphera, Inc. [TLPH]

Upcoming Earnings Alert